HDR UK Gateway
HDR Gateway logo

Bookmarks

CCU016: Cardiovascular and cerebrovascular diseases related to antipsychotic prescribing in patients with dementia during the COVID-19 pandemic

Safe People

Organisation name

University of Edinburgh

Organisation sector

Academic Institute

Applicant name(s)

Tim Wilkinson

Sub-licence arrangements (if any)?

No

Safe Projects

Project ID

CCU016

Lay summary

People living with dementia have been amongst the hardest hit during the COVID-19 pandemic. A group of drugs called ‘antipsychotics’ are sometimes used to treat distress and agitation in people living with dementia. However, there is evidence to suggest that these medicines may increase the risk of stroke and heart attacks when given to people with dementia. They should therefore only be used as a last resort, when other treatments have failed. Since March 2020, the prescribing of these drugs for people with dementia has increased. We think this may be because social distancing restrictions have caused more people to need treatment for distress or agitation as they do not have access to their normal support structures. This increase in antipsychotic prescribing during the COVID-19 pandemic is concerning, as it may have led to an increase in heart attacks and strokes in these patients. We will investigate whether this increase in antipsychotic prescribing has led to an increase in strokes or heart attacks. To do this, we will use information that is collected routinely by health services, such as GP records, prescriptions and diagnoses recorded in hospital. We hope that the results of this study will help inform decision making between doctors, patients and carers, by enabling them to weigh up the risks and benefits of prescribing an antipsychotic.

Public benefit statement

We will investigate whether this increase in antipsychotic prescribing has led to an increase in strokes or heart attacks. To do this, we will use information that is collected routinely by health services, such as GP records, prescriptions and diagnoses recorded in hospital. We hope that the results of this study will help inform decision making between doctors, patients and carers, by enabling them to weigh up the risks and benefits of prescribing an antipsychotic. Visit the BHF Data Science Centre website for more detailed information about project outputs. https://bhfdatasciencecentre.org/projects/ccu016/

Technical summary

This project accessed the following datasets within the Trusted Research Environment(s) for CVD-COVID-UK / COVID-IMPACT: - WALES: - Annual District Death Daily (ADDD) - Annual District Death Extract (ADDE) - Care Home Dataset (CARE) - COVID-19 Consolidated Deaths (CDDS) - COVID-19 Test Results (PATD) - Patient Episode Dataset for Wales (PEDW) - SAIL Dementia e-Cohort (SDEC) - Welsh Demographic Service Dataset (WDSD) - Welsh Dispensing Dataset (WDDS) - Legacy - Welsh Longitudinal General Practice Dataset (WLGP) - Welsh Primary Care

Latest approval date

29/04/2021

Safe Data

Dataset(s) name

Data sensitivity level

De-Personalised

Safe Setting

Access type

TRE